Earl Martin Douglas - 14 Aug 2023 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
GENERAL COUNSEL
Signature
/s/Earl Douglas
Issuer symbol
ALLO
Transactions as of
14 Aug 2023
Net transactions value
$0
Form type
4
Filing time
17 Aug 2023, 18:57:35 UTC
Next filing
31 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +108,958 $0.000000 108,958 14 Aug 2023 Direct F1
transaction ALLO Common Stock Award $0 +326,876 +300% $0.000000 435,834 14 Aug 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to Buy) Award $0 +960,854 $0.000000 960,854 14 Aug 2023 Common Stock 960,854 $4.13 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Constitutes Performance Restricted Stock Units ("PRSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each PRSU upon vesting, 50% shall vest in the event the Company achieves a 30-day weighted average share price of $18 on or before March 22, 2026 and 50% shall vest upon the first marketing approval of a Company product by the US FDA on or before March 22, 2028.
F2 25% of the shares subject to the stock option shall vest on August 14, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.